维生素K环氧降解酶复杂子单元1 (VKORC1) 基因多态性预测慢性病患者的动脉硬性和血清MGP水平
David H Chen1, Cees Vermeer2, John R Cockcroft3
1Division of Experimental Medicine & Immunotherapeutics, University of Cambridge, Cambridge CB2 0QQ, UK.
Genes
|December 30, 2025
概括
特定的维生素K环氧减少酶基因 (VKORC1) 多态性显著影响慢性病 (CKD) 患者的动脉硬性和维生素K依赖蛋白水平. 这些发现强调了维生素K在血管健康和CKD进展中的作用.
科学领域:
- 心血管医学 心血管医学
- 腎臟病學 (nephrology) 是一種醫學.
- 遗传学 遗传学 是一个
背景情况:
- 动脉硬是心血管风险的标志物,在慢性病 (CKD) 中,随着功能下降而恶化.
- 维生素K依赖蛋白质和VKORC1基因变异在血管健康,特别是动脉硬性中的作用在CKD中仍然基本未被探索.
- 这项研究调查了常见的VKORC1基因多态化与慢性病患者动脉硬和化的标志物之间的关联.
研究的目的:
- 检查特定VKORC1基因多态化对动脉刚性和化的影响.
- 评估VKORC1基因型与总非碳氧化矩阵Gla蛋白 (t-uncMGP) 的血清水平之间的关系.
- 探索维生素K依赖途径在CKD血管并发症中的潜在作用.
主要方法:
- 招募了302名患有慢性病的患者.
- 评估血压,大动脉脉冲波速 (aPWV),冠状动脉化 (CAC) 和大动脉化 (AC).
- 基因型的VKORC1多态 (-1639G>A, +1173C>T, +1542G>C, +2255C>T, +3730G>A) 和测量的血清t-uncMGP水平.
主要成果:
- +1542G>C和+3730G>A的VKORC1多态与较高的aPWV和较低的t-uncMGP水平有关.
- 一个结合的衰退性等位基因模型揭示了aPWV在增加风险等位基因的逐步减少.
- 每个+1542G等位基和+3730A等位基独立增加了aPWV分别为0.8m/s和1.0m/s,经过对共变量进行调整后.
- 血清t-uncMGP水平与CAC得分相反相关,但VKORC1基因型与化没有直接关联.
结论:
- VKORC1多态 (+1542G>C和+3730G>A) 是慢性病患者动脉硬性的新型决定因素.
- 这些遗传变异影响t-uncMGP水平,表明维生素K依赖的过程在血管健康中的作用.
- 这些发现表明,维生素K依赖的途径可能在CKD的背景下调节动脉硬和血管化.
相关概念视频
01:28Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
158
Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.
158
01:25Chronic Kidney Disease I: Introduction
531
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
531
01:24Chronic Kidney Disease II: Clinical Manifestations
516
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
516
01:28Chronic Kidney Disease III: Interprofessional Care
316
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
316
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
214
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
214